此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer

2013年6月5日 更新者:National Cancer Institute (NCI)

Randomized Phase II Study of Thalidomide Versus Thalidomide Plus Fludarabine for Patients With Chronic Lymphocytic Leukemia Previously Treated With Fludarabine

This randomized phase II trial is studying thalidomide and fludarabine to see how well they work compared to thalidomide alone in treating patients with hematologic cancer that has not responded to previous treatment with fludarabine. Thalidomide may stop the growth of hematologic cancer by stopping blood flow to the cancer. Combining thalidomide with fludarabine may increase the effectiveness of chemotherapy by making cancer cells more sensitive to the drug. It is not yet known whether thalidomide is more effective with or without fludarabine for hematologic cancer.

研究概览

详细说明

OBJECTIVES:

I. Compare the safety and tolerability of thalidomide with or without fludarabine in patients with fludarabine-refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

II. Compare the incidence of complete and partial remission in patients treated with these regimens.

OUTLINE: This is a randomized, open-label study. Patients are stratified according to time to relapse from last fludarabine treatment (less than 6 months vs more than 6 months). Patients are randomized to one of two treatment arms.

Arm I: Patients receive oral thalidomide once daily in the absence of disease progression or unacceptable toxicity.

Arm II: Patients receive thalidomide as in arm I and fludarabine IV over 30 minutes on days 1-5. Treatment with fludarabine repeats every 28 days for 6 courses. Once fludarabine is completed, patients continue to receive thalidomide alone as in arm I.

PROJECTED ACCRUAL: A total of 24-70 patients (12-35 per treatment arm) will be accrued for this study within 1 year.

研究类型

介入性

注册 (实际的)

70

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • New York
      • Bronx、New York、美国、10467-2490
        • Montefiore Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Diagnosis of one of the following:

    • Confirmed chronic lymphocytic leukemia (CLL), meeting the following criteria:

      • Peripheral blood lymphocytosis greater than 5,000/mm^3
      • Co-expression of the CD5, CD19, CD20, and CD23 surface antigens
      • Clonal kappa and lambda light chain expression
      • Dim surface immunoglobulin expression
    • Small lymphocytic lymphoma
  • Relapsed or refractory disease

    • Must have received at least 1 prior regimen containing fludarabine
    • Meets one of the following criteria:

      • Recurrence of lymphocytosis greater than 5,000/mm^3 or an increase in lymph node volume greater than 50% after achieving complete (CR) or partial response (PR)
      • Never achieved a CR or PR after receiving at least 2 courses of fludarabine IV for 5 days at a dose of 25 mg/m^2/day
  • No other lymphoproliferative diseases or diseases due to transformation of CLL (e.g., prolymphocytic leukemia or Richter's syndrome)
  • No known CNS disease
  • Performance status - Karnofsky 60-100%
  • At least 12 weeks
  • See Disease Characteristics
  • Bilirubin < 2.0 times upper limit of normal (ULN)*
  • SGOT < 2.5 times ULN*
  • Creatinine < 1.5 times ULN
  • No history of cardiac arrhythmia
  • No myocardial infarction within the past 6 months
  • No other malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix
  • No active serious infection uncontrolled by antibiotics
  • No pre-existing neurotoxicity grade 3 or greater
  • No other medical condition that would preclude study participation
  • Not pregnant or nursing
  • Negative pregnancy test
  • Female patients must use 2 effective methods (at least 1 highly active method) of contraception 4 weeks before, during, and for 4 weeks after study participation and male patients must use effective barrier contraception during and for 4 weeks after study participation
  • At least 4 weeks since prior biologic therapy and recovered
  • No concurrent growth factors (epoetin alfa, filgrastim [G-CSF], or sargramostim [GM-CSF])
  • See Disease Characteristics
  • No more than 3 prior chemotherapy regimens
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered
  • No other concurrent chemotherapy
  • At least 4 weeks since prior radiotherapy and recovered
  • No concurrent radiotherapy
  • Recovered from any prior investigational agents
  • No other concurrent investigational agents

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Arm I (thalidomide)
Patients receive oral thalidomide once daily in the absence of disease progression or unacceptable toxicity.
口头给予
其他名称:
  • 凯瓦顿
  • 舒诺韦
  • 塔尔
  • 沙洛米
实验性的:Arm II (thalidomide, fludarabine phosphate)
Patients receive thalidomide as in arm I and fludarabine IV over 30 minutes on days 1-5. Treatment with fludarabine repeats every 28 days for 6 courses. Once fludarabine is completed, patients continue to receive thalidomide alone as in arm I.
鉴于IV
其他名称:
  • 2-F-ara-AMP
  • 益氟乐
  • 氟达拉
口头给予
其他名称:
  • 凯瓦顿
  • 舒诺韦
  • 塔尔
  • 沙洛米

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Toxicities graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0
大体时间:Up to 5 years
Up to 5 years
Incidence of complete and partial remission
大体时间:Up to 5 years
Up to 5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Richard Furman、Montefiore Medical Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2002年3月1日

初级完成 (实际的)

2006年11月1日

研究注册日期

首次提交

2001年2月2日

首先提交符合 QC 标准的

2003年1月26日

首次发布 (估计)

2003年1月27日

研究记录更新

最后更新发布 (估计)

2013年6月6日

上次提交的符合 QC 标准的更新

2013年6月5日

最后验证

2013年6月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅